【Abstract】 Objective To explore efficacy and safety of Marvelon combined with and without Mirena intrauterine placement in the treatment of adenomyosis. Methods 84 adenomyosis patients from July 2014 to December 2015 were enrolled in the study and randomly divided into Marvelon group and combined group, each group with 42 cases, which were treated with Marvelon and Marvelon combined with Mirena respectively. 1 month, 3 months and 6 months after treatment, variations on dysmenorrhea score, menstruation volume, serum CA125 level, uterine volume and adverse reactions were observed. Results The dysmenorrhea scores after 1month, 3 months and 6 months of Combined group (154±049，097±031，062±023) were all significantly lower than that of Marvelon group (178±054，120±037，083±029) (P＜005). The menstruation volume scores 3 months and 6 months after treatment (7860±1145，6750±1053) were significantly lower than that of Marvelon group (9055±1567，8283±1409)(P＜005). CA125 level 3 months and 6 months after treatment ［（8588±2452）U/ml，（7145±1951）U/ml］were significantly lower than that of Marvelon group ［(10221±2944)U/ml, (9088±2333)U/ml］ (P＜005). The uterine volume after treatment of the two groups showed no significant differences (P＞005). The incidences of adverse reactions of the two groups during treatment had no statistically significant differences (P＞005). Conclusion Marvelon combined with Mirena can further relieve clinical symptoms and reduce CA125 level, and with no increase of adverse reactions of adenomyosis.